🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma [Mon, Dec 11, 2023: 11:15a] Laura Cogrossi et al. #ASH23 Abst 754 ash.confex.com/ash/2023/webpr… #IDonc #ImmunoOnc #mmsm

“We are not alone” reminders at #ASH2023 Terrific session about gut microbiota and hematological malignancies this morning

It has been a great honor to present our work about #microbiota and #immunotherapy preventing the progression of #MM #SMM at #ASH2023! New connections and new interesting interactions! Thanks ASH and CellularImmune_lab for the support

Kicking off the DITID24 retreat: amazing talk by our stellar Laura Cogrossi of CellularImmune_lab outlying how immune microbiote shape the immune sistem in Multiple Myeloma

Most important slide of my presentation at divisional #DITID #retreat in Brescia! As always thank to CellularImmune_lab and happy to share new perspectives going on in our division Ospedale San Raffaele

Great performance for Giovanni Pastorino at his first divisional #DITID Retreat! Interesting fusion between lab and clinic

Understanding the dynamics of the gut #Microbiota over the course of #Cancer treatment regimens and their associated adverse events can help identify microbial features that associate with response to immune checkpoint blockade. nature.com/articles/s4159…

A paper in Nature Medicine reports on efforts to identify microbial signatures of response to immune checkpoint blockade that suggest that strain-level associations may be cancer type agnostic but cancer therapy specific. go.nature.com/3V2JgLx

Growing evidence shows that dietary interventions can be effective at treating or delaying some diseases, but further trials are needed for wider adoption (especially in cancer) Nature Medicine nature.com/articles/s4159…

New paper out in today Nature Communications! 🎉🎉With Mayo Clinic University of Miami Sylvester Comprehensive Cancer Center Leif Bergsagel, Marta Chesi, Coffey D we integrated #wgs #scrna to show how Vk*MYC Mouse genomic evolution mimics the one observed in human myeloma #mmsm (1/xx) 🧵👇

Let’s fight cancer together Fondazione AIRC per la ricerca sul cancro

Doing a PhD #PhD #PhDlife #academics #AcademicChatter #AcademicTwitter

Out in Journal of Clinical Oncology our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum. #NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31. 22 pts

Pts with an ypT0N0 response had lower baseline fraction of PMN cells (CD15+CD45+) compared to ypT</=1N0 responders and nonresponders (ypT≥2N0 and ypN+) Longitudinal analyses showed that at C2D1 the fraction of CD11b+CD33+CD14+HLA-DRlow/int monocytic myeloid cells increased in

Novel data finally out on muscle-invasive #bladdercancer #neoadjuvant therapy. Glad to have contributed to #immunebiomarker analysis ⁦CellularImmune_lab⁩ ⁦Andrea Necchi⁩ ascopubs.org/doi/10.1200/JC…

Finally out!! Neoadjuvant Nivo + ABX with 35.7% pCR and nearly 70% pMR in MIBC regardless of platinum eligibility. Lower PB fraction of PMN-MDSCs and intermediate monocyte in pCR but at baseline only. CD11b+CD33hi monos increase from baseline to C2D1. Next step: SG +/- Pembro

Excited to share results from Nutrivention trial and mouse study to prevent progression from #smm to #myeloma at #cicon24 in Washington DC. Great environment and shared interest in cancer #immunotherapy. Acknowledgments to ⁦Urvi Shah⁩ leading the clinical study.

Honored to be selected to share our work during #diet and #microbiota session with amazing speakers. #FMT, #microbiota-based therapies and #nutrition the novel pillars for cancer prevention and immunotherapy #Cicon24 Cancer Research Institute

Today’s issue of The Washington Post The Washington Post keeps up with #cicon24 topics! #fibers plant-based #diet. Perfect meeting conclusion just before takeoff

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive #BladderCancer brnw.ch/21wMC1Y Andrea Necchi #blsm